Australia
· Delayed Price · Currency is AUD Noxopharm Statistics
Total Valuation
Noxopharm has a market cap or net worth of AUD 20.75 million. The enterprise value is 16.57 million.
| Market Cap | 20.75M |
| Enterprise Value | 16.57M |
Important Dates
The next estimated earnings date is Tuesday, June 3, 2025.
| Earnings Date | Jun 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Noxopharm has 292.24 million shares outstanding.
| Current Share Class | 292.24M |
| Shares Outstanding | 292.24M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.79% |
| Owned by Institutions (%) | 1.71% |
| Float | 195.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.85 |
| PB Ratio | 4.80 |
| P/TBV Ratio | 4.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.15 |
| EV / Sales | 7.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.92
| Current Ratio | 4.92 |
| Quick Ratio | 4.86 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.82 |
Financial Efficiency
Return on equity (ROE) is -42.50% and return on invested capital (ROIC) is -52.79%.
| Return on Equity (ROE) | -42.50% |
| Return on Assets (ROA) | -45.58% |
| Return on Invested Capital (ROIC) | -52.79% |
| Return on Capital Employed (ROCE) | -105.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.70% in the last 52 weeks. The beta is 0.14, so Noxopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +12.70% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 41.83 |
| Average Volume (20 Days) | 81,644 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Noxopharm had revenue of AUD 2.34 million and -2.32 million in losses. Loss per share was -0.01.
| Revenue | 2.34M |
| Gross Profit | -690,282 |
| Operating Income | -4.60M |
| Pretax Income | -2.32M |
| Net Income | -2.32M |
| EBITDA | -4.60M |
| EBIT | -4.60M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 4.18 million in cash and n/a in debt, giving a net cash position of 4.18 million or 0.01 per share.
| Cash & Cash Equivalents | 4.18M |
| Total Debt | n/a |
| Net Cash | 4.18M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 4.32M |
| Book Value Per Share | 0.01 |
| Working Capital | 4.35M |
Cash Flow
| Operating Cash Flow | -4.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -29.44%, with operating and profit margins of -196.31% and -98.79%.
| Gross Margin | -29.44% |
| Operating Margin | -196.31% |
| Pretax Margin | -98.79% |
| Profit Margin | -98.79% |
| EBITDA Margin | -196.23% |
| EBIT Margin | -196.31% |
| FCF Margin | n/a |
Dividends & Yields
Noxopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -11.16% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Noxopharm has an Altman Z-Score of -6.55. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.55 |
| Piotroski F-Score | n/a |